CytomX Therapeutics, Inc.
CTMXNasdaqCIK 1501989HealthcareFiscal year ends Dec 31
Reports and events: 196 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-0620:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338009 |
| 2026-08-0620:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-337950 |
| 2026-07-2712:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-316929 |
| 2026-06-2220:52 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-277631 |
| 2026-06-0320:15 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-26-255467 |
| 2026-05-0720:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211920 |
| 2026-05-0720:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-211868 |
| 2026-04-3020:16 ET | DEF 14A | Proxy statementPeriod 2026-06-17 | 0001140361-26-018237 |
| 2026-03-1920:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-115958 |
| 2026-03-1611:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-107152 |
| 2026-03-1611:01 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-107146 |
| 2025-11-0621:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269533 |
| 2025-11-0621:07 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269477 |
| 2025-08-1312:07 ET | 8-K | 8.01 Other events | 0001193125-25-179463 |
| 2025-08-0720:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-105053 |
| 2025-08-0720:06 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104991 |
| 2025-06-1320:07 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-140739 |
| 2025-05-2820:06 ET | 8-K | 8.01 Other events | 0001193125-25-129470 |
| 2025-05-1320:05 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-118805 |
| 2025-05-1210:25 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-117245 |
| 2025-05-1210:14 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-068511 |
| 2025-04-2820:15 ET | DEF 14A | Proxy statementPeriod 2025-06-11 | 0001140361-25-016026 |
| 2025-03-0621:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-034585 |
| 2025-03-0621:01 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-034575 |
| 2025-02-2621:30 ET | 8-K | 3.01 Delisting notice | 0001193125-25-036794 |
| 2025-02-0321:02 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-019257 |
| 2025-01-0621:10 ET | 8-K | 2.05 Exit or disposal costs | 0001193125-25-002165 |
| 2024-11-0721:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-123314 |
| 2024-11-0721:02 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123249 |
| 2024-08-0820:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093936 |
| 2024-08-0820:03 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093865 |
| 2024-06-1720:35 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-162652 |
| 2024-05-1720:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-141699 |
| 2024-05-0820:41 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-134284 |
| 2024-05-0820:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055598 |
| 2024-05-0820:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-055588 |
| 2024-04-0420:31 ET | DEF 14A | Proxy statementPeriod 2024-05-15 | 0001140361-24-017969 |
| 2024-03-2220:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-075211 |
| 2024-03-1120:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-029207 |
| 2024-03-1120:00 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-029191 |
| 2023-11-0721:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-060221 |
| 2023-11-0721:00 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-060201 |
| 2023-08-2420:05 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-23-220087 |
| 2023-08-0820:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-039793 |
| 2023-08-0820:03 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-039761 |
| 2023-07-0323:07 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-23-180722 |
| 2023-06-2020:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-23-170124 |
| 2023-05-0920:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-019674 |
| 2023-05-0920:09 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-019654 |
| 2023-04-2720:16 ET | DEF 14A | Proxy statementPeriod 2023-06-14 | 0001140361-23-020944 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:12 ET. Listed shows no prices and gives no investment advice.